Key Insights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

1 of 0 completed with results

Key Signals

1 with results0

3Total

P 2 (2)

P 4 (1)

Not Yet Recruiting1

Recruiting1

Terminated1

Clinical Trials (3)

Showing 3 of 3 trials

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL

Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

Showing all 3 trials